Myeloma UK has shared its report with the Government, NICE, the pharmaceutical industry and anyone involved in getting treatments approved.
Over the coming months the charity says it will meet with key decision-makers to discuss how to take the reports’ recommendations forward and give patients faster and fairer access to treatment in the UK.
A NICE spokesperson said: “Over the last five years, NICE has approved 90% of cancer treatments it has appraised, rising to 94% in 2025/26, demonstrating our commitment to helping patients access effective new treatments as quickly as possible.
“We have made significant changes to speed up patient access to innovative new medicines while ensuring decisions remain grounded in robust evidence and fair value for the NHS.
“For people with multiple myeloma, earlier access has been supported through the Cancer Drugs Fund with around 21,000 people treated since 2016, around one in six patients helped by the Fund.
“NICE is also using simpler, faster routes for some treatments, while keeping the same high standards. For some medicines, this has already cut the time taken to produce guidance by up to 20 weeks.”
